Stem cells and immune cells are currently a hot topic and frontier field in medical research, and one of the most promising biotechnology industries in the world. From vigorously developing the "stem cell application" to the "big health industry" of the entire industry chain of "health care and treatment", more and more research applications have shown that stem cells and immune cells have good application prospects in hematological, cardiovascular and cerebrovascular diseases, neurological diseases, digestive diseases, self metabolic diseases, and malignant tumors.

Aiwei aims to industrialize cell preparation and strictly follows industry standards such as the "Good Manufacturing Practice (GMP)" and "Good Manufacturing Practice for Stem Cell Preparations" to establish a GMP standard "B+A" clinical preparation center. Aiwei has established a standalone cell quality control center to resolutely implement strict quality control (cell and material inspection, environmental testing, etc.) and quality assurance (production process control and monitoring), ensuring the safety and effectiveness of cells. At present, Aiwei has cooperated with many hospitals to carry out relevant clinical research on record in the Health Commission, laying a solid foundation for the declaration of stem cell drugs, and preparing research level and clinical level cell preparations as required for scientific research and hospital institutions inside and outside the province.